Bayer to Produce CureVac Vaccine in Germany
February 01 2021 - 6:42AM
Dow Jones News
By Joshua Stein and Ulrike Dauer
Bayer AG will expand its partnership with CureVac NV to produce
the company's Covid-19 vaccine candidate in Germany, the companies
said in a joint press conference Monday.
Bayer intends to make millions of doses of CureVac's mRNA
vaccine at its facilities in Germany, Bayer Head of Pharmaceuticals
Stefan Oelrich said.
"We expect to produce 160 million doses in the first 12 months
and will increase vaccine production to significantly more than 160
million doses in the second year," Mr. Oelrich said.
The first commercial product from the expanded partnership may
be available towards the end of 2021, Bayer said.
CureVac and Bayer will begin Phase-3 tests of the vaccine in the
coming weeks, said German Health Minister Jens Spahn, who was also
at the press conference.
"Following discussions with the German government it has become
clear that current manufacturing capacities for vaccines need to be
increased, particularly for potential variants of the SARS-CoV-2
virus," Mr. Oelrich said.
Bayer was already working with CureVac on its vaccine candidate
by supporting the company in the areas of infrastructure,
regulatory affairs, pharmacovigilance, medical information,
supply-chain management and country operations within the European
Union, Bayer said.
Write to Joshua Stein at joshua.stein@wsj.com
(END) Dow Jones Newswires
February 01, 2021 06:27 ET (11:27 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
Bayer (TG:BAYN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Bayer (TG:BAYN)
Historical Stock Chart
From Sep 2023 to Sep 2024